[
  {
    "ts": null,
    "headline": "Abbott increases quarterly dividend for 54th consecutive year",
    "summary": "Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%. The company's quarterly dividend payout has increased more than 70% since 2020.",
    "url": "https://finnhub.io/api/news?id=7841529272ff1495c139e3889a8decfd990242cadbd6aa237cef43feebc90a9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765553160,
      "headline": "Abbott increases quarterly dividend for 54th consecutive year",
      "id": 137769435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%. The company's quarterly dividend payout has increased more than 70% since 2020.",
      "url": "https://finnhub.io/api/news?id=7841529272ff1495c139e3889a8decfd990242cadbd6aa237cef43feebc90a9a"
    }
  },
  {
    "ts": null,
    "headline": "What Is Driving Hologic's Strength in the US Diagnostics Market?",
    "summary": "HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.",
    "url": "https://finnhub.io/api/news?id=44662edd71641dd444487659ba3be117ecdf2e593801efc88fcc289cd17907d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765542840,
      "headline": "What Is Driving Hologic's Strength in the US Diagnostics Market?",
      "id": 137769436,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.",
      "url": "https://finnhub.io/api/news?id=44662edd71641dd444487659ba3be117ecdf2e593801efc88fcc289cd17907d7"
    }
  },
  {
    "ts": null,
    "headline": "Autoimmune Disease Diagnosis Market to Surge to USD 8.98 Billion by 2031",
    "summary": "The autoimmune disease diagnosis market is poised to grow from USD 5.57 billion in 2025 to USD 8.98 billion by 2031, exhibiting a CAGR of 8.3%. Key growth drivers include rising autoimmune disorder prevalence, increased awareness of early detection, and technological advances. Systemic autoimmune diseases lead in market share due to conditions like rheumatoid arthritis and lupus necessitating complex diagnostics. The Asia Pacific region is the fastest-growing, driven by healthcare advancements.",
    "url": "https://finnhub.io/api/news?id=75a71738f8a891e1a7801dd74bcc21e66161a539a32b63b5cb006981f2018af3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765538880,
      "headline": "Autoimmune Disease Diagnosis Market to Surge to USD 8.98 Billion by 2031",
      "id": 137766979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The autoimmune disease diagnosis market is poised to grow from USD 5.57 billion in 2025 to USD 8.98 billion by 2031, exhibiting a CAGR of 8.3%. Key growth drivers include rising autoimmune disorder prevalence, increased awareness of early detection, and technological advances. Systemic autoimmune diseases lead in market share due to conditions like rheumatoid arthritis and lupus necessitating complex diagnostics. The Asia Pacific region is the fastest-growing, driven by healthcare advancements.",
      "url": "https://finnhub.io/api/news?id=75a71738f8a891e1a7801dd74bcc21e66161a539a32b63b5cb006981f2018af3"
    }
  },
  {
    "ts": null,
    "headline": "Did FDA-Approved Hugo Robot and New Diabetes Tech Just Shift Medtronic's (MDT) Investment Narrative?",
    "summary": "In early December 2025, Medtronic’s board approved a US$0.71 per-share cash dividend for the third quarter of fiscal 2026, payable on January 16, 2026, and the company secured FDA clearance for its Hugo robotic-assisted surgery system in urologic procedures while launching its MiniMed 780G system with Abbott’s Instinct sensor across the U.S. Together, these developments highlight how Medtronic is pairing a long-running dividend growth record with fresh momentum in robotics and diabetes...",
    "url": "https://finnhub.io/api/news?id=f098d5d3d513abc12e06f79ae4afead26a58c9ed54908a5cf64abd6be78f6a10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765530778,
      "headline": "Did FDA-Approved Hugo Robot and New Diabetes Tech Just Shift Medtronic's (MDT) Investment Narrative?",
      "id": 137766985,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "In early December 2025, Medtronic’s board approved a US$0.71 per-share cash dividend for the third quarter of fiscal 2026, payable on January 16, 2026, and the company secured FDA clearance for its Hugo robotic-assisted surgery system in urologic procedures while launching its MiniMed 780G system with Abbott’s Instinct sensor across the U.S. Together, these developments highlight how Medtronic is pairing a long-running dividend growth record with fresh momentum in robotics and diabetes...",
      "url": "https://finnhub.io/api/news?id=f098d5d3d513abc12e06f79ae4afead26a58c9ed54908a5cf64abd6be78f6a10"
    }
  },
  {
    "ts": null,
    "headline": "November $10B+ M&A Deals Set Q4 Up To Outpace Prior Quarter",
    "summary": "November's announced M&A deals of more than $10 billion in transaction value brought the fourth quarter's worldwide tally to 11 deals. Read more here.",
    "url": "https://finnhub.io/api/news?id=e5f87c881aeb4646c8a5a77d597c11e5e733f60fba9cef8a69a1ef431d12f517",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765519200,
      "headline": "November $10B+ M&A Deals Set Q4 Up To Outpace Prior Quarter",
      "id": 137766183,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2222078293/image_2222078293.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "November's announced M&A deals of more than $10 billion in transaction value brought the fourth quarter's worldwide tally to 11 deals. Read more here.",
      "url": "https://finnhub.io/api/news?id=e5f87c881aeb4646c8a5a77d597c11e5e733f60fba9cef8a69a1ef431d12f517"
    }
  },
  {
    "ts": null,
    "headline": "2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore",
    "summary": "Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.",
    "url": "https://finnhub.io/api/news?id=0b3a8e3d7e7696d2436f71f8ac60b466834a9cfcf766e2b7663ffd58a4e4ddee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765513925,
      "headline": "2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore",
      "id": 137770380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.",
      "url": "https://finnhub.io/api/news?id=0b3a8e3d7e7696d2436f71f8ac60b466834a9cfcf766e2b7663ffd58a4e4ddee"
    }
  }
]